The GYG1 Knockout SK-HEP-1 Polyclonal Cells represent a CRISPR/Cas9-mediated gene disruption model targeting the human GYG1 locus in the SK-HEP-1 cell line. Supplied as a heterogeneous polyclonal population, these cells provide a robust loss-of-function platform to study glycogenin-1 deficiency without clonal isolation. The polyclonal format preserves population-level genetic diversity while ensuring consistent knockout across the cell pool, suitable for bulk biochemical and functional analyses.
The parental SK-HEP-1 cell line is a human liver adenocarcinoma epithelial line isolated from the ascitic fluid of a patient with liver adenocarcinoma. Exhibiting both epithelial morphology and endothelial-like characteristics, SK-HEP-1 cells are widely employed as a model for hepatocellular carcinoma (HCC) and for dissecting hepatic metabolic processes. Their dual phenotype makes them particularly valuable for investigating the interplay between hepatic glucose handling and tumor progression.
GYG1 encodes glycogenin-1, a glycosyltransferase that initiates glycogen synthesis by autoglucosylation, forming a short oligosaccharide primer. This primer is then extended by glycogen synthase (GYS1, GYS2) and branched by GBE1, with regulatory control from insulin, glucose, FOXO1, and PPARGC1A. Glycogenin-1 physically interacts with glycogen synthase, PPP1R3C (a protein phosphatase 1 regulatory subunit), GNIP/TRIM7, and UDP-glucose, positioning it at the nexus of glycogen assembly. Disruption of GYG1 abolishes primer formation, blocking glycogen accumulation and profoundly altering cellular energy storage and stress responses.
In the SK-HEP-1 background, GYG1 knockout creates a physiologically relevant system for examining how loss of glycogen synthesis impacts HCC cell metabolism. Given that SK-HEP-1 cells retain features of liver sinusoidal endothelial cells and hepatocytes, this model is particularly suited to dissect glycogen’s role in tumor bioenergetics, proliferation under nutrient stress, and sensitivity to metabolic interventions. It also serves as an in vitro correlate for glycogen storage disease type XV, which involves glycogenin-1 mutations leading to muscle glycogen depletion and cardiomyopathy.
These polyclonal knockout cells enable a broad spectrum of experimental applications. Investigators can perform PAS staining and enzymatic glycogen quantification to confirm depletion, assess glucose uptake and utilization via 2-NBDG assays, measure mitochondrial respiration and glycolysis using Seahorse analyzers, and profile transcriptional changes by RNA-seq. The cells are also ideal for screening small-molecule modulators of glycogenin-1 or downstream partners like PPP1R3C. For further technical details, contact Ascent Research.
